XPO1 and asthma: The same group then used a virtual screen to look for compounds that bound CRM1, and determined that Zafirlukast (Figure 2C), a leukotriene receptor antagonist that is FDA approved for asthma, bound the NES of CRM1 in pull-down experiments.